Two clinical pilot studies with HER2-negative breast cancer patients demonstrate STF as a feasible, tolerated intervention in both trials and a reduction in the hematological toxicity of chemotherapy treatment in one trial [248, 251]. The gene discussed is ERBB2; the disease is breast cancer.